宜宾哪里有开双眼皮的宜宾哪里割双眼皮手术好得快,宜宾眼睛太小怎么变大,宜宾鼻子大可以缩小,宜宾韩式隆鼻的价格,在宜宾割双眼皮大约需要多少钱,宜宾美杜莎双眼皮多少钱,宜宾哪家医院祛斑较好

BEIJING, Oct. 13 (Xinhuanet) -- Scientists have decoded the genome of Black Death which caused one of the worst plagues in human history.The finding was published Wednesday in the scientific journal Nature.A team of German, Canadian and American scientists collected the bacteria's DNA from ancient plague victims' teeth and bones, which were excavated from the burial ground in London.With a careful NDA comparison between the ancient bacteria and the modern strains, scientists found the direct variant of the medieval bacteria still exist today.Black Death's descendants kill around 2,000 people a year, mostly in the developing world, the scientist said."This will provide us with direct insights into the evolution of human pathogens and historical pandemics," said Johannes Krause Of Germany's University of Tubingen, who worked on the study.Black Death, the fatal plague of medieval Europe, wiped out some 30 million people -- about 50 percent of the population on the continent, within just five years, between 1347 and 1351.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

SEOUL, Nov. 28 (Xinhua) -- Samsung Electronics, the world's second-largest manufacturer of mobile phones, said Monday that it launched its latest smart mobile gadget Galaxy Note in South Korea in a bid to take the lead in a new phase of the mobile phone market.The Galaxy Note, which was first introduced in September at IFA 2011, the consumer electronics fair held in Berlin, was Samsung's latest Galaxy lineup, combining the portability of a smartphone with the larger screen of a tablet computer, according to Samsung.The device ensured portability and grip with 9.65-millimeter thin, 182 grams in weight and a rounded back design, while featuring a 5.3-inch super active-matrix organic light-emitting diode (AMOLED) display.The function of "S Pen," or a digital pen, was added to the device in a bid to enable users to draw, paint and crop images by writing on the screen, Samsung said.Featuring Android's 2.3 Gingerbread platform, the gadget was powered by a 1.5-gigahertz dual core processor supplemented with fourth generation (4G) long term evolution (LTE) network service."Galaxy Note is a revolutionary product opening a new category in the market. It will deliver a whole new mobile experience beyond feature phones, smartphones and tablet devices," said Shin Jong-kyun, president and head of Samsung's mobile communications business.In addition, Samsung launched Galaxy Nexus, the world's first smartphone running Android's 4.0 Ice Cream Sandwich. The latest Android operating system (OS) combined the benefits of smartphones and tablet computers, according to Samsung.The smartphone, which was first introduced in Hong Kong last month, offered quicker multi-tasking and faster web browsing than previous models, while the near-field communication (NFC) function allowed users to easily share contents with other users by tapping their devices together, Samsung said.With the updated Ice Cream Sandwich, the Galaxy Nexus offered facial recognition technology, which unlocks the phone by identifying the user's face.

WASHINGTON, Nov. 21 (Xinhua) -- The launch of the Mars Science Laboratory, which contains the car-sized Curiosity rover, has been delayed by a day to Nov. 26, the U.S. National Aeronautics and Space Administration (NASA) announced Monday.The delay will "allow time for the team to remove and replace a flight termination system battery," NASA said in a statement.The launch is now scheduled for 10:02 a.m. (1502 GMT) on Saturday from Cape Canaveral Air Force Station, Florida. The launch window remains open for one hour and 43 minutes.Curiosity is about twice as long and more than five times as heavy as any previous Mars rover. Its 10 science instruments include two for ingesting and analyzing samples of powdered rock delivered by the rover's robotic arm.Scheduled to land on the Mars in August 2012, the one-ton rover will examine Gale Crater during a nearly two-year prime mission. Curiosity will land near the base of a layered mountain three miles (five kilometers) high inside the crater. The rover will investigate whether environmental conditions ever have been favorable for development of microbial life and preserved evidence of those conditions.